Novartis Seeks Approval for Gleevec in Four Rare Cancers

EAST HANOVER, New Jersey—Novartis has submitted supplemental NDAs for imatinib (Gleevec) as treatment for four rare types of cancer. The diseases, all with Gleevec-sensitive pathways, are dermatofibrosarcoma protuberans, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and systemic mastocytosis.